Schwazze (SHWZ)
OTHER OTC:SHWZ
Top Page
No summary available
Positive Factors
Revenue Growth
Consistent revenue growth indicates expanding market presence and product demand, supporting long-term business sustainability.
Negative Factors
High Leverage
High leverage can strain financial resources and limit flexibility, posing risks to long-term financial health and stability.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Consistent revenue growth indicates expanding market presence and product demand, supporting long-term business sustainability.
Read all positive factors
Schwazze (SHWZ) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$78.00
Dividend YieldN/A
Average Volume (3M)15.75K
Price to Earnings (P/E)―
Beta (1Y)-741.28
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees729
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)N/A
Shares Outstanding78,248,390
10 Day Avg. Volume31,966
30 Day Avg. Volume15,754
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.33
Price to Sales (P/S)0.23
P/FCF Ratio24.82
Enterprise Value/Market Cap2.21M
Enterprise Value/Revenue0.99
Enterprise Value/Gross Profit3.07
Enterprise Value/Ebitda11.38
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Schwazze Business Overview & Revenue Model
Company Description
Medicine Man Technologies, Inc., doing business as Schwazze, operates as a cannabis company. It operates through three segments: Retail, Wholesale, and Other. The company offers cannabis products that include loose flower, concentrates, edibles, p...
How the Company Makes Money
Medicine Man Technologies generates revenue through multiple channels within the cannabis industry. Its primary revenue streams include the sale of cannabis products through its retail dispensaries and wholesale distribution. The company also earn...
Schwazze Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | TTM | Dec 2023 | Dec 2022 | Mar 2022 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 174.91M | 172.45M | 159.38M | 108.42M | 24.00M | 10.62M |
| Gross Profit | 56.31M | 76.02M | 85.03M | 49.35M | 6.77M | 3.00M |
| EBITDA | 15.16M | 38.19M | 38.12M | 34.51M | -19.80M | -13.40M |
| Net Income | -59.68M | -34.55M | -18.47M | 14.52M | -19.42M | -16.98M |
Balance Sheet | ||||||
| Total Assets | 339.61M | 358.14M | 322.92M | 285.03M | 70.68M | 32.23M |
| Cash, Cash Equivalents and Short-Term Investments | 12.39M | 19.71M | 39.40M | 106.40M | 1.23M | 11.85M |
| Total Debt | 198.19M | 191.87M | 148.23M | 106.33M | 21.55M | 66.80K |
| Total Liabilities | 248.82M | 238.85M | 190.76M | 151.46M | 28.91M | 5.65M |
| Stockholders Equity | 90.79M | 119.29M | 132.16M | 133.57M | 41.77M | 26.58M |
Cash Flow | ||||||
| Free Cash Flow | -1.47M | 1.59M | -3.42M | 51.67M | -10.57M | -7.75M |
| Operating Cash Flow | 6.59M | 12.20M | 11.39M | 57.33M | -9.80M | -7.55M |
| Investing Cash Flow | -8.06M | -26.44M | -79.18M | -81.16M | -33.22M | -1.12M |
| Financing Cash Flow | -6.14M | -5.46M | 843.81K | 129.00M | 31.90M | 20.20M |
Schwazze Technical Analysis
Negative
0.01
Price Trends
0.02
Negative
0.02
Negative
0.08
Negative
Market Momentum
>-0.01
Positive
21.38
Positive
-3.51
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SHWZ, the sentiment is Negative. The current price of 0.01 is below the 20-day moving average (MA) of 0.02, below the 50-day MA of 0.02, and below the 200-day MA of 0.08, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 21.38 is Positive, neither overbought nor oversold. The STOCH value of -3.51 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SHWZ.
Schwazze Risk Analysis
Schwazze disclosed 66 risk factors in its most recent earnings report. Schwazze reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 2 New Risks
1.
Fines, judgments and other consequences resulting from our failure to comply with regulations or adverse outcomes in litigation proceedings could adversely affect our business, financial condition, results of operations and prospects. Q4, 2023
2.
If our relationship with our employees were to deteriorate, we may be faced with unionization efforts, labor shortages, disruptions or stoppages, which could adversely affect our business and reduce our operating margins and revenue. Q4, 2023
Schwazze Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
| ― | $78.00 | ― | ― | ― | ― | ― | |
59 Neutral | $352.51M | -37.26 | -1.44% | ― | 1.76% | 18.31% | |
49 Neutral | $40.52M | -4.80 | -199.09% | ― | -86.05% | 24.17% | |
44 Neutral | $763.39M | ― | -91.00% | ― | 2.31% | -726.28% | |
40 Underperform | $2.11M | -0.71 | -93.87% | ― | -0.74% | 81.49% |
* Healthcare Sector Average
SHWZ
Schwazze
0.01
-0.01
-50.00%
TLRY
Tilray
6.55
0.76
13.09%
SNDL
SNDL
1.36
0.03
2.26%
IMCC
IM Cannabis Corp
0.34
-0.97
-74.12%
IXHL
Incannex Healthcare Limited Sponsored ADR
2.90
-11.90
-80.40%
Schwazze Corporate Events
Business Operations and StrategyM&A TransactionsPrivate Placements and Financing
Schwazze Enters Restructuring Agreement with Vireo Growth
Positive
Oct 14, 2025
On October 10, 2025, Medicine Man Technologies, Inc., operating as Schwazze, entered into a Restructuring Support Agreement (RSA) with Vireo Growth Inc. to restructure its operations and capital structure. This involves the sale of a majority of t...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―